Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
TTPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MNKMallinckrodt Plc
-0.28%35.9721.1%$138.29m
PRGOPerrigo Co. Plc
-1.88%74.076.7%$126.06m
SHPGShire PLC Sponsored ADR
0.46%171.430.4%$113.20m
ENDPEndo International Plc
-1.95%15.608.9%$89.97m
JAZZJazz Pharmaceuticals Plc
-0.16%173.972.2%$72.74m
ICPTIntercept Pharmaceuticals, Inc.
3.50%107.0018.7%$69.26m
SAGESAGE Therapeutics, Inc.
3.81%153.879.6%$58.93m
UTHRUnited Therapeutics Corporation
2.46%128.1114.4%$52.33m
CTLTCatalent Inc
0.70%41.582.6%$48.31m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.41%137.496.8%$42.64m
PTLAPortola Pharmaceuticals, Inc.
1.20%25.327.7%$42.29m
SUPNSupernus Pharmaceuticals, Inc.
-0.11%44.356.2%$40.49m
ICLRICON Plc
1.41%143.944.2%$39.20m
ZGNXZogenix, Inc.
0.86%46.9011.9%$38.19m
HZNPHorizon Pharma plc
-0.63%20.507.4%$33.41m

Company Profile

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.